Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

OncBioMune Provides Update on Market Activity

Posted on: 16 Feb 18

BATON ROUGE, La., Feb. 16, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, wishes to make the following statements regarding recent market activity in its common stock traded on the OTCQB marketplace.

On February 12, 2018, the Company was informed by OTC Markets about certain promotional activity in relation to OBMP common stock, including newsletter emails.  From time to time, the Company engages investor relations services to provide advertising and communication services for news and corporate information.  Since January 1, 2017, the Company has engaged RCI, American Capital Ventures, Inc. and Viper Enterprises LLC.  All communications are to remain within parameters of public information and corporate facts.  Neither the Company, its officers, directors or to its knowledge any shareholders participate in material creation or have any control in its content or dissemination.   Until being notified by OTC Markets, the Company was unaware of the identified promotional activity and remains unaware of the full nature of any promotional activity or the extent of its dissemination.  The Company, to its knowledge, has not compensated the creators of the identified promotional activity.    None of the statements regarding the fundamentals of the Company brought to the attention of the Company were materially false or misleading.  Since being informed by OTC Markets, the Company has not engaged any additional investor relations, advertising and communications services and has no current intentions of doing so going forward.   

The Company attributes any increase in trading volumes to news of a letter of intent with an esteemed urology clinic in Texas, disbanding of the joint venture in Mexico as filed with the Securities and Exchange Commission to focus on domestic development of ProscaVax for prostate cancer and developments with a major Northeastern U.S. university for a Phase 2 trial of ProscaVax for early-stage prostate cancer.  The Company has also increased the number of issued and outstanding common stock over the past few months due to the conversions of convertible notes, as discussed below, which can contribute to increased volume levels.   

Neither of the company's executive officers or directors, nor, to the knowledge of the company, any controlling shareholders sold or purchased shares of common stock of the company within the past 90 days (or anytime in recent years for that matter).  Leadership remains steadfast in commitment to develop shareholder value through pipeline development.

In order to fund ProscaVax development and general corporate expenses, the Company previously issued convertible debentures, as disclosed with details readily available through regular filings with the Securities and Exchange Commission in current reports filed on January 30, 2018,  July 26, 2017, June 6, 2017 and November 28, 2016.  In recent months, these convertible instruments have been being converted into equity securities at prices discounted to the market price of OBMP stock at the time of issuance, per the issued securities’ terms. 

The Company is committed to compliance with the OTC Markets Group policy on stock promotion and the OTCQB standards. The Company encourages those interested in the Company to rely solely on information included in press releases issued and distributed by the Company through approved news wire or disclosure and news services, combined with its filings and disclosures made with the Securities and Exchange Commission, as well as information provided through the OTC Markets and OncBioMune websites.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, based on their proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. Our lead pipeline product, ProscaVax™, has successfully completed enrollment and vaccination of the prostate cancer patients and is collecting long-term follow-up results for the 1a portion of their Phase 1a/1b clinical trial.  Due to the impressive results and proven safety profile of ProscaVax™, OncBioMune is forgoing the 1b portion of the trial to advance ProscaVax™ into Phase 2 studies.  A Phase 2 trial is scheduled to commence at a major Northeast U.S. university cancer research hospital evaluating ProscaVax as a front-line therapy in prostate cancer patients in the “active surveillance” category, representing the first mid-stage trial of an immunotherapeutic vaccine in this patient population.  OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.


OncBioMune Pharmaceuticals, Inc.
Andrew Kucharchuk
President and Chief Financial Officer


Last updated on: 20/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.